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ABSTRACT 
Objective:  To assess Ang-1, Ang-2 and the Ang-1/Ang-2 ratio levels in the first trimester of 
pregnancy, their association with adverse pregnancy outcomes; and their predictive accuracy. 
Study Design: This cohort study measured serum Ang-1 and Ang-2 levels in 4,785 women 
with singleton pregnancies attending first trimester screening in New South Wales, Australia. 
Multivariate logistic regression models were used to assess the association and predictive 
accuracy of serum biomarkers with subsequent adverse pregnancy outcomes (small for 
gestational age, preterm birth, preeclampsia, miscarriage >10 weeks and stillbirth). 
Results: Median (interquartile range) levels for Ang-1, Ang-2 and the Ang-1/Ang-2 ratio for 
the total population were 19.6 ng/ml (13.6-26.4), 15.5 ng/ml (10.3-22.7) and 1.21 (0.83-1.73), 
respectively. Maternal age, weight, country of birth and socio-economic status significantly 
affected Ang-1, Ang-2 and the Ang-1/Ang-2 ratio levels. After adjusting for maternal and 
clinical risk factors, women with low Ang-2 levels (<10th centile) and high Ang-1/Ang-2 
ratio (>90th centile) had increased risk of developing most adverse pregnancy outcomes. 
Compared to the Ang-1/Ang-2 ratio alone, maternal and clinical risk factors had better 
predictive accuracy for most adverse pregnancy outcomes. The exception was miscarriage 
[Ang-1/Ang-2 ratio area under ROC curve (AUC) =0.70; maternal risk factors AUC =0.58]. 
Overall, adding the Ang-1/Ang-2 ratio to maternal risk factors did not improve the ability of 
the models to predict adverse pregnancy outcomes.  
Conclusions: Our findings suggest that the Ang-1/Ang-2 ratio in first trimester is associated with 
most adverse pregnancy outcomes, but do not predict outcomes any better than clinical and 
maternal risk factor information.  
Keywords: Angiopoietins, Ang-1 Ang-2, first trimester, serum levels, adverse pregnancy outcomes 
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INTRODUCTION  
 
Neovascularisation, or new vessel formation, is essential for placental growth throughout 
gestation and is driven by changes in the balance between pro- and anti-angiogenic factors 
present in the extracellular milieu.1 Angiopoietin 1 (Ang-1) and angiopoietin 2 (Ang-2) are 
angiogenic factors that play a critical role in the development of the placental vascular 
system. While Ang-1 helps capillary maturation and maintains vessel integrity, Ang-2 
antagonises Ang-1 and destabilizes vessels. In the presence of pro-angiogenic factors, such as 
vascular endothelial growth factor (VEGF) or placental growth factor (PlGF), this 
destabilisation results in vessel sprouting and enhanced angiogenesis.2 More than just vessel 
growth, signalling from angiopoietins is a significant stimulus for trophoblast growth and 
remodelling during placentation.  Thus, the interplay between Ang-1, Ang-2, and other 
angiogenic factors (such as VEGF) controls placental growth and tissue neovascularisation 
during pregnancy.3  It is not therefore surprising that the amount of circulating Ang-1 and 
Ang-2 shifts from a dominance of Ang-1 to Ang-2 during gestation reflecting the requirement 
for new vessel formation.4  
 
Impaired placental vascular development related to imbalances in angiogenic factors are 
implicated in pathological pregnancies. As such, Ang-1 and Ang-2 are potential biomarkers 
for adverse pregnancy outcomes as they indicate the progression of placental growth and 
maternal vascular health during gestation.4 Circulating levels of Ang-1 and Ang-2 have 
previously been associated with poor pregnancy outcome. We have reported that women 
whose fetuses develop intrauterine growth restriction (IUGR) have lower serum levels of 
Ang-2 in first trimester, suggesting impaired placental angiogenesis may be pathogenic in the 
disease.5 Others have reported lower serum Ang-1 and Ang-2 in women that had an abortion 
or an ectopic pregnancy, with promising predictive results.6 Preeclampsia has been associated 
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with both low second trimester levels of Ang-27 and low ratio of Ang-1/Ang-2.8 However, 
these studies included a small number of cases and did not report results for other adverse 
pregnancy outcomes. There are no large population-based studies assessing the association of 
Ang-1 and Ang-2 in early pregnancy and risk of subsequent pregnancy outcomes. It is also 
unknown whether these angiogenic biomarkers provide any additional value to usual 
maternal and clinical information identifying pregnancies at risk.   If women at risk of 
developing adverse pregnancy outcomes can be identified early in pregnancy this would 
allow ample time for monitoring and implementing potential preventive strategies. 
 
 
The aims of this study were three-fold; i) to evaluate serum levels of serum Ang-1, Ang-2 
concentrations and Ang-1/Ang-2 ratio in first trimester of pregnancy. ii) to assess the 
association between maternal serum Ang-1, Ang-2 concentrations and the Ang-1/Ang-2 ratio 
and risk of adverse pregnancy outcomes; and iii) to determine their accuracy in predicting 
adverse pregnancy outcomes.  
 
MATERIALS AND METHODS 
Study population and sample testing 
This cohort study was conducted on women attending first trimester Down syndrome 
screening between July 2006 and June 2007 in New South Wales (NSW), Australia. Serum 
samples were collected by the Pacific Laboratory Medicine Services (PaLMs), and then 
archived and stored at -80°C. During this period, this was the state’s only public screening 
service and received samples from throughout NSW. 
 
Serum samples for this study were thawed and serum levels of Ang-1 and Ang-2 were 
measured by a semi-automated ELISA immunoassay (R & D Systems, Minneapolis, MN, 
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USA). Intra-assay and inter-assay coefficient of variation were <9.5% and the reported 
analytic sensitivity of the immunoassay was 0.06 – 84.3 ng/ml for Ang-1 and 0.05 – 108.9 
ng/ml for Ang-2.  
 
Data sources 
Maternal information for archived serum samples was derived from the laboratory database 
and corresponding pregnancy and birth outcomes were ascertained via record linkage to the 
Perinatal Data Collection (PDC) and Admitted Patient Data Collection (APDC). The PDC is 
a statutory surveillance system of all births in NSW of at least 400 grams birth weight, or at 
least 20 weeks’ gestation and includes demographic, medical and obstetric information on the 
mother, labour, delivery and birth outcome.  The APDC is a census of all patient hospital 
admissions from NSW public and private hospitals, with records for both mothers and 
liveborn infants. It includes demographic, clinical and health services information for each 
admission and relevant diagnoses and procedures are recorded for each hospital admission. 
These are coded according to the International Classification of Diseases version 10 – 
Australian Modification (ICD10-AM) and Australian Classification of Healthcare 
Interventions, respectively. Validation studies of the PDC and the APDC show excellent level 
of agreement with the medical record and low rates of missing data.9, 10 Reporting in both 
datasets have high specificity (> 99%) indicating few false positive reports. Only factors and 
outcomes accurately reported in birth or hospital data were included in analyses.11 The NSW 
Centre for Health Record Linkage conducted the record linkage and identifying information 
was removed prior to the release of data for analysis. The CHeReL assesses the linkage 
quality for each study, and for this study reported <5/1000 missed links and <2/1000 false 
positive links.  The study was approved by the NSW Population and Health Services 
Research Ethics Committee. 
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Study outcomes and explanatory factors assessed included: small for gestational age (SGA), 
preterm birth, preeclampsia, gestational diabetes, miscarriage and stillbirth. SGA was defined 
as birthweight less than the 10th centile and less than the 3rd centile (severe SGA) of the 
distribution for gestational age and infant sex.12 Gestational age is reported in the birth data in 
completed weeks of gestation and determined by the best clinical estimate including early 
ultrasound (>97%) and last menstrual period. Preterm birth was defined as delivery at less 
than 37 weeks and very preterm birth less than 34 weeks gestation. Information on 
preeclampsia was obtained from both the APDC and PDC data, to maximize ascertainment.13, 
14 Preeclampsia (regardless of severity) was determined either by the box being checked in 
the PDC record, or if any APDC record had a diagnosis in any of the 55 fields of gestational 
hypertension (ICD10-AM: O13 and O16), preeclampsia (O11 and O14) or eclampsia 
(O15).14, 15 Early onset preeclampsia was defined as women with preeclampsia requiring 
delivery at ≤34 weeks gestation.  Miscarriage was defined as a spontaneous pregnancy loss 
between 10-20 weeks gestation and identified from APDC data, while stillbirth was defined 
as a spontaneous pregnancy loss after 20 weeks gestation and was identified from PDC data. 
To replicate an earlier study of ours, we defined a proxy measure of IUGR using combined 
criteria of SGA<10th centile and preterm birth <37weeks.  
 
The key explanatory variables were Ang-1, Ang-2 and the Ang-1/Ang-2 ratio levels and 
covariates used in this analysis included maternal age and weight (kilograms) ascertained at 
the time of first trimester screening, parity (nulliparous/multiparous), smoking during 
pregnancy, previous diagnosed hypertension, previous miscarriage, country of birth and 
socio-economic disadvantage quintile. Socio-economic disadvantage was defined according 
to the Socio-Economic Indexes for Areas (SEIFA) relative disadvantage scores developed by 
the Australian Bureau of Statistics (ABS).16 Maternal weight was missing in 831 (16.3%) of 
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the records. Multiple imputation was used to account for the missing maternal weight, a 
method that predicts missing values using existing values from other variables.17 Other 
missing data were uncommon and were excluded from the analyses: smoking was missing in 
55 (1.2%) and country of birth in 3 (0.1%) of the records. 
 
Statistical analysis 
Comparison of Ang-1, Ang-2 and the Ang-1/Ang-2 ratio by maternal characteristics for 
women with and without each clinical outcome was performed using contingency tables and 
student’s t-test analysis for categorical and normaly distributed variables, respectively. 
Spearman coefficient was used to determine the correlation between Ang-1 and Ang-2. To 
account for differences in Ang-1 and Ang-2 values attributable to gestational week of the test, 
maternal age and weight, we standardized Ang-1 and Ang-2 levels using Multiple of the 
Medians (MoM). Kruskall-Wallis test was used to compare concentrations of Ang-1, Ang-2 
and the Ang-1/Ang-2 ratio between women that subsequently had adverse pregnancy 
outcomes with women with unaffected pregnancies. If MoM levels were either decreased or 
elevated, they were dichotomized by the <10th or the >90th centile, respectively. Multivariate 
logistic regression was then used to assess the association between serum biomarkers with 
adverse pregnancy outcomes, taking into account maternal and clinical risk factors.  A 
backward elimination method retaining only significant explanatory variables was used to fit 
models for each outcome.   
 
Predictive accuracy was assessed examining the area under the Receiver Operating 
Characteristics (ROC) curves (AUC), derived from logistic regression analysis and using log 
transformed levels to achieve Gaussian distribution.  AUC results were examined to 
determine whether models performed better than chance (0.5). Models for serum biomarkers 
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alone, those including maternal and clinical risk factors only and with serum biomarkers and 
risk factors combined were compared. This approach was applied to assess whether serum 
levels of Ang-1 and Ang-2 provided any additional information to maternal and clinical risk 
factors in predicting severe adverse pregnancy outcomes by evaluating the maximum 
likelihood estimates using the likelihood ratio (X2) test. Finally, estimates of predictive 
accuracy at a fixed 5% false positive rate were calculated including sensitivity, specificity, 
positive (PPV), negative predictive values (NPV) and positive likelihood ratio (LR) with 
exact binominal confidence intervals. A P-value of <0.05 was considered statistically 
significant and analyses performed using SAS software 9.3 (SAS Institute Inc., Cary, NC, 
USA).  
 
RESULTS 
A total of 5,183 samples were tested with health information relevant to the pregnancy 
available for 4,785 (92.3%) samples. We excluded 164 women whose blood sample was 
taken before 10 or after 14 weeks gestation; had a medical abortion, had a twin pregnancy or 
had an infant with a major congenital anomaly. Ang-1 and Ang-2 were undetectable in 111 
and 52 samples, respectively, and these women were assigned a value equal to half the 
detection limit. A total of 4,621 women were included in the analysis. 
 
Figure 1 presents a scatter plot between Ang-1 and Ang-2 serum levels, illustrating a positive 
correlation between Ang-1 and Ang-2 (r =0.26, P<0.001). Table 1 presents the median (IQR) 
serum levels of Ang-1, Ang-2 and the Ang-1/Ang-2 ratio by maternal characteristics. The 
mean (SD) maternal age and weight were 32.9 (4.7) years and 66.6 (14.3) kilograms, 
respectively. Almost half (n=2,108; 46.4%) of women were nulliparous, 279 (6.1%) smoked 
during pregnancy and 187 (4.1%) had previous diagnosed hypertension. The median serum 
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levels of Ang-1, Ang-2 and the Ang-1/Ang-2 ratio for total population were 19.7 ng/ml (IQR: 
13.9 - 26.7), 16.3 ng/ml (IQR: 10.7 - 23.9) and 1.2 (IQR: 0.8 - 1.7), respectively. Serum 
Ang-1, Ang-2 levels and the Ang-1/Ang-2 ratio showed significant variation by maternal 
weight, country of birth and socio-economic disadvantage (Table 1), and there was a positive 
correlation between maternal weight and Ang-1/Ang-2 ratio (r =0.07, P<0.001). While Ang-1 
and the Ang-1/Ang-2 ratio levels decreased with gestational week at sampling, Ang-2 levels 
did not change. There was also an increase in serum Ang-1 and Ang-2 with maternal age 
(Table 1).  
 
The median (IQR) serum levels, both raw and MoM adjusted for Ang-1, Ang-2 and the Ang-
1/Ang-2 ratio in pregnancies affected by adverse outcomes are presented in Table 2. 
Compared with unaffected pregnancies (1.02; IQR: 0.69 – 1.48), median serum levels of 
Ang-2 MoM were decreased for SGA <10th centile (0.90; IQR: 0.60 – 1.26), SGA <3rd 
centile (0.90; IQR: 0.61 – 1.24), preterm birth <37 weeks (0.89; IQR: 0.62 – 1.34), 
preeclampsia (0.92; IQR: 0.60 – 1.36) and miscarriage (0.59; IQR: 0.31 – 1.18).  The Ang-
1/Ang-2 ratio was also increased for SGA <10th centile, SGA <3rd centile, preterm birth <37 
weeks, preterm birth <34 weeks, preeclampsia, early onset preeclampsia and miscarriage due 
mostly to the decreased Ang-2 levels. There was no difference in Ang-1 levels between 
women with unaffected pregnancies with women who had adverse pregnancy outcomes 
(Table2). 
 
The association of low Ang-2 MoM (<10th centile) and high Ang-1/Ang-2 ratio MoM (>90th 
centile) with adverse pregnancy outcomes is presented in Table 3. Ang-2 <10th centile (Ang-2 
<0.44 MoM) was associated with 40% increased risk of SGA<10th centile and preterm birth 
(<37 weeks) and a threefold increased risk of miscarriage. The Ang-1/Ang-2 ratio MoM 
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>90th centile (ratio >1.73 MoM) was associated with a near twofold increased risk of SGA, 
preterm birth, preeclampsia and an almost sevenfold increased risk of miscarriage. When our 
proxy of IUGR was considered (N=30), the adjusted odds ratios were 4.01 (95% confidence 
interval (CI) 1.76, 9.13) and 4.24 (95%CI 1.98, 9.10) for Ang-2 <10th centile and the Ang-
1/Ang-2 ratio MoM >90th centile, respectively. 
 
Figure 2 present the accuracy for the Ang-1/Ang-2 ratio in predicting adverse pregnancy 
outcomes. The AUC for models of the Ang-1/Ang-2 ratio alone models revealed a negligible 
discriminative ability in predicting most of the adverse pregnancy outcomes (AUC<0.6), 
compared with maternal risk factors (best accuracy for early-onset preeclampsia: AUC=0.71; 
LR=6.17). Adding information on Ang-1/Ang-2 ratio to maternal risk factors did not improve 
the ability of the models to predict adverse pregnancy outcomes, except in the case of 
miscarriage (Ang-1/Ang-2 AUC=0.70; P>0.001; LR=5.89). Sensitivity was 27.8% for 
miscarriage but less than 10% for the rest of the outcomes. The NPV was over 93% for all 
pregnancy outcomes, but particularly high for severe cases (>97%), indicating that women 
that do not have high Ang-1/Ang-2 ratio in early pregnancy were unlikely to have subsequent 
SGA<3rd infant, early-onset preeclampsia or miscarriage.  
 
COMMENT 
We have conducted the largest population-based study to examine maternal Ang-1 and Ang-2 
levels of women in first trimester, and to assess the association with adverse pregnancy 
outcomes. Our study highlights that Ang-1 and Ang-2 are positively correlated and there is 
significant variation in Ang-1 and Ang-2 levels, and the Ang-1/Ang-2 ratio by maternal 
characteristics and week of sampling. Women that developed adverse pregnancy outcomes 
had lower serum levels of Ang-2 and higher levels of the Ang-1/Ang-2 ratios, compared with 
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women with unaffected pregnancies. Results suggest that the interaction of both biomarkers, 
proposed as a ratio, strengthens the association with adverse pregnancy outcomes compared 
with Ang-2 alone.  However, with the exception of miscarriage, the accuracy of the Ang-
1/Ang-2 ratio in predicting most adverse pregnancy outcomes was poor and did not add 
predictive information to routinely collected maternal and clinical risk factors. 
 
Previous studies have evaluated the association of first trimester serum Ang-1 and/or Ang-2 
levels with adverse pregnancy outcomes and their characteristics are summarized in Table 4. 
Three studies reported Ang-1 levels ranging from 0.96 and 27.8ng/ml in unaffected women.6-
8 Nine studies assessed Ang-2 levels and reported to vary widely (median Ang-2 ranging 
between 1.4 and 33.2 ng/ml).5-8, 18 Although all studies utilized the same assay for analysis 
(R&D systems), differences in population characteristics and sampling time may account for 
variations in serum levels of Ang-2. Studies assessing the association of serum Ang-1 and 
Ang-2 levels with subsequent adverse pregnancy outcomes have reported conflicting results. 
Reduced serum Ang-2 at 10 -13 weeks was found among women that gave birth to an infant 
diagnosed with  intra uterine growth restriction (IUGR) 5 and low Ang-1 and Ang-2 levels 
were found at 6-8 weeks among women with subsequent missed abortion/ectopic pregnancy.6 
In contrast, three studies reported no association between Ang-2 levels with preeclampsia,7, 8, 
18  while two of them found that women with preeclampsia had higher serum Ang-2 and 
lower Ang-1/Ang-2 ratio in second trimester, compared to unaffected women.7, 8 These 
results represent a converse association compared with ours and other studies that assessed 
serum Ang-2 at term.19, 20 Although, these studies may be limited to small sample size, 
inclusion of Caucasian women only and exclusion women with pre-existing disease, the 
precise explanation for these inconsistent results remains unknown.  
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The exact mechanism of how Ang-2 is regulated in unaffected versus preeclamptic 
pregnancies is still unidentified perhaps due to the multi factorial origin of preeclampsia.  Our 
recent data indicated that while the placenta is a key source of Ang-2 during uncomplicated 
pregnancies it is the decidua that is likely to be the primary source.21 Release of Ang-2 from 
the decidua is from both active secretion and new synthesis of Ang-2 protein.21 We also noted 
an effect of gestational age on the levels of Ang-2 produced by decidual cells with serum 
from first trimester inducing greater release than that from third trimester.  Thus, circulating 
factors present in early pregnancy, and declining throughout gestation, appear to control Ang-
2 release.  Normal placental development occurs in a hypoxic environment,22 stimulating 
angiogenesis through the transcriptional activator hypoxia-inducible factor-1α (HIF-1α).  
Two of the most prominent HIF-1α targets are the pro-angiogenic factor genes such as VEGF 
and Ang-2.23  Thus, this might explain the reported up-regulation of Ang-2 early in 
pregnancy and why it decreases after first trimester.21  However, preeclampsia is associated 
with chronic hypoxia, either intermittent or persistent,24 yet Ang-2 mRNA levels are reduced 
in preeclamptic placentas.4  Thus, the raised Ang-1/Ang-2 ratio observed in preeclampsia 
here may reflect additional aspects of the disease, such as inflammation, which are known to 
be regulated by Ang-2 levels.  Moreover, if the association of Ang-1/Ang-2 ratio with 
inflammation was stronger in these diseases then that may explain why elevated ratios are 
associated with pregnancy outcomes that are known to have inflammation as part of their 
pathogenesis, such as preterm birth, preeclampsia and miscarriage.25-27 
 
Our results suggest that the Ang-1/Ang-2 ratio may be a promising biomarker for 
miscarriage.  Especially as women with recurrent miscarriage have reduced blood vessel 
expression of Ang-2 related to premature advanced vessel maturation.28 To date, one case-
control study  has also reported a strong association and good predictive accuracy of Ang-1 
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and Ang-2 for missed abortion and ectopic pregnancy.6 However, these were measured at 6-8 
weeks gestation. Our results for miscarriage must be interpreted with caution as miscarriage 
is under ascertained. First, women had to reach 10 weeks to be eligible for screening and 
second, only miscarriages resulting in admission to hospital can be identified. Further 
research exploring and replicating this association is warranted. 
 
Strengths of the study were the evaluation of a large sample from population-based cohort of 
pregnant women attending first trimester screening. Ascertainment and follow-up of 
pregnancy outcomes was possible for 92% of the samples using record linkage of laboratory 
to birth and hospital data with only minimal missing information. Missing health and 
pregnancy information was mostly attributable to women giving birth in hospitals out of 
state. Yet, women with missing information had similar characteristics compared with those 
included in the study. 
One of the limitations of the study was maternal weight missing in 16% of the women, which 
was addressed by applying multiple imputation, a technique shown to be robust and valid for 
dealing with missing data.17 We did not have access to BMI information which has been 
found to have a significant interaction with angiogenic gene polymorphisms when predicting 
pre-term birth.29, 30 BMI information may have allowed us to refine our models to increase 
the predictive accuracy of angiopoietins. Another limitation of the study was the differences 
between our cohort compared with the state total maternity population during the same 
period, which may be due to a healthier and more affluent population. We tackled this 
limitation by weighting our analyses to ensure generalizability of the results.  
 
In conclusion, our findings suggest that the Ang-1/Ang-2 ratio in first trimester is associated 
with most adverse pregnancy outcomes, but do not predict outcomes any better than clinical 
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and maternal risk factor information. Our results indicate a potential role of the Ang-1/Ang-2 
ratio in first trimester as a predictive marker for subsequent miscarriage, but this requires 
further investigation.  
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Table 1: First trimester An-1, Ang-2 and the Ang-1/Ang-2 ratio serum levels by maternal 
characteristics   
 
 Maternal 
characteristics 
n (%) 
Ang-1 (ng/ml) 
Median (IQR) 
Ang-2 (ng/ml) 
Median (IQR) 
Ang-1/Ang-2 
ratio           
Median (IQR) 
Total 4621 19.6 (13.6, 26.4) 15.5 (10.3, 22.7) 1.21 (0.83, 1.73) 
Matenal age         
<25  267 (5.8) 18.9 (12.7, 24.4) 13.9 (10.4, 21) 1.27 (0.81, 1.65) 
25 - 29  892 (19.3) 19.2 (12.8, 25.7) 14.9 (9.2, 22.7) 1.20 (0.85, 1.73) 
30 - 34  1862 (40.3) 19.9 (13.9, 27.2) 16.0 (10.6, 23.4) 1.21 (0.82, 1.76) 
35 - 39  1368 (29.6) 20.9 (14.9, 28.2) 16.8 (11.4, 24.4) 1.20 (0.83, 1.73) 
40+  232 (5.0) 20.1 (15.1, 27.3) 16.8 (10.7, 25.6) 1.11 (0.79, 1.74) 
  
 
P=0.0011 P=0.001 P=0.8 
Parity 
    
Nulliparous 2108 (46.4) 19.4 (14.0, 26.2) 15.9 (10.6, 23.3) 1.17 (0.80, 1.64) 
Parous 2436 (53.6) 19.8 (13.0, 26.6) 15.2 (10.3, 22.5) 1.24 (0.84, 1.75) 
  
 
P=0.6 P=0.6 P=0.02 
Smoking during pregnancy 
   
Yes 279 (6.1) 19.7 (13.0, 24.9) 14.3 (10.3, 21.3) 1.28 (0.88, 1.63) 
No 4287 (93.9) 19.6 (13.6, 26.8) 15.7 (10.4, 23.0) 1.20 (0.82, 1.73) 
  
 
P=0.1 P=0.04 P=0.3 
Maternal weight (kg) 
    
<55 658 (17.3) 19.7 (14.1, 26.1) 19.1 (13.2, 27.1) 0.98  (0.67, 1.32) 
55 - 64 846 (22.3) 18.6 (13.0, 25.3) 17.2 (11.4, 24.5) 1.08 (0.72, 1.55) 
65 - 74 736 (19.4) 19.1 (12.2, 25.0) 15.8 (9.9, 22.8) 1.16 (0.78, 1.63) 
75 - 84 790 (20.8) 18.8 (13.5, 24.5) 14.0 (10.3, 22.0) 1.24 (0.85, 1.75) 
85+ 766 (20.2) 21.7 (14.5, 29.1) 13.0 (8.8, 18.4) 1.60 (1.10, 2.32) 
  
 
P<.001 P<.001 P<.001 
Gestational week at sampling 
   
10 520 (11.3) 22.7 (16.2, 29.5) 14.3 (9.9, 22.1) 1.47 (1.00, 2.21) 
11 1651 (35.7) 20.3 (14.1, 26.9) 15.8 (10.3, 22.9) 1.21 (0.88, 1.73) 
12 1772 (38.3) 19.1 (13.0, 25.8) 15.6 (10.3, 23.0) 1.19 (0.79, 1.66) 
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13 678 (14.7) 18.5 (13.3, 24.7) 15.7 (10.4, 22.2) 1.17 (0.81, 1.61) 
  
 
P<.001 P=0.2 P<.001 
Country of birth 
    
Australia & New 
Zealand 
3032 (67.0) 19.7 (13.4, 26.2) 15.0 (10.1, 22.2) 1.27 (0.87, 1.76) 
Pacific Islands 45 (1.0) 19.5 (10.5, 26.7) 17.4 (11.6, 19.8) 1.35 (0.69, 2.50) 
Europe, NA & SA 530 (11.7) 20.5 (14.0, 26.7) 16.9 (11.8, 25.4) 1.07 (0.75, 1.52) 
Middle east 96 (2.1) 18.7 (12.8, 24.7) 15.9 (10.9, 21.9) 1.06 (0.72, 1.60) 
South east Asia 254 (5.6) 22.1 (15.1, 28.5) 18.2 (11.3, 25.7) 1.17 (0.82, 1.74) 
China, Hong Kong & 
Taiwan 
216 (4.8) 18.9 (14.0, 26.7) 19.5 (13.6, 28.8) 0.97 (0.64, 1.38) 
Japan and Koreas 126 (2.8) 19.2 (13.9, 24.9) 16.8 (13.0, 26.2) 1.00 (0.68, 1.33) 
India & surroundings 154 (3.4) 19.0 (12.2, 28.7) 12.8 (7.3, 21.6) 1.26 (0.80, 2.01) 
Central and South 
America 
51 (1.1) 19.5 (16.6, 26.8) 12.7 (10.9, 23.2) 1.38 (0.89, 1.70) 
Africa and Caribbean 22 (0.5) 14.1 (10.7, 22.5) 12.6 (6.4, 20.3) 1.20 (0.85, 1.39) 
  
 
P=0.01 P<.001 P<.001 
SEIFA Socio-economic disadvantage quintile 
  
1   (most disadvantage) 365 (7.9) 20.9 (14.8, 29.1) 15.5 (10.8, 22.2) 1.28 (0.89, 1.79) 
2 580 (12.6) 19.9 (13.5, 26.0) 14.6 (9.8, 21.9) 1.28 (0.86, 1.78) 
3 779 (16.9) 18.7 (13.2, 25.0) 14.9 (10.1, 22.5) 1.19 (0.79, 1.75) 
4 669 (14.5) 17.5 (12.2, 24.7) 14.8 (9.5, 21.4) 1.16 (0.83, 1.64) 
5   (least disadvantage) 2205 (48.0) 20.0 (14.1, 26.7) 17.0 (11.1, 24.5) 1.13 (0.79, 1.61) 
  
P<.001 P<.001 P<.001 
 
1 P-values for Kruskall-Wallis test; NA: North America; SA: South Africa; SEIFA: Socio-Economic Indexes for Areas 
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  Table 2. Demographic characteristics and serum levels of Ang-1 and Ang-2 of the study population by pregnancy outcome  
Maternal characteristics 
Median Ang-1 
ng/ml (IQR) 
Median Ang-1 
MoM (IQR) 
Median Ang-2 
ng/ml (IQR) 
Median Ang-2 
MoM (IQR) 
Median          
Ang-1/Ang-2 
ratio (IQR) 
Median          
Ang-1/Ang-2 
ratio MoM (IQR) 
Unaffected (n=3730)          19.6 (13.8, 26.4)  0.98 (0.69, 1.32) 16.6 (11.0, 24.4) 1.02 (0.69, 1.48) 1.14 (0.79, 1.62) 0.93 (0.65, 1.30) 
SGA<10th centile (n=445)    18.7 (13.7, 25.8) 0.94 (0.71, 1.30) 14.8 (10.0, 22.3)* 0.90 (0.60, 1.26)* 1.25 (0.84, 1.75) 1.05 (0.74, 1.50)* 
SGA<3rd centile (n=109)  17.7 (13.5, 26.3)  0.91 (0.71, 1.30)  14.1 (10.8, 21.7)  0.90 (0.61, 1.24)*  1.19 (0.77, 1.77)  1.09 (0.70, 1.54)* 
Preterm birth <37 weeks (n=310) 19.5 (13.8, 29.1)  0.97 (0.70, 1.41) 14.3 (9.4, 22.4)*  0.89 (0.62, 1.34)*  1.37 (0.89, 1.97)*  1.06 (0.72, 1.51)* 
Preterm birth <34 weeks (n=84)  18.3 (15.2, 25.1)   0.93 (0.76, 1.33)  14.4 (9.9, 21.1)   0.90 (0.65, 1.21)   1.38 (0.90, 1.97)*   1.07 (0.73, 1.53) 
All preeclampsia (n=163)  20.8 (15.4, 28.3)   1.05 (0.80, 1.39)  14.7 (9.2, 20.2)*   0.92 (0.60, 1.36)   1.44 (0.98, 1.96)*   1.12 (0.75, 1.65)* 
Early-onset preeclampsia  (n=14) 18.1 (16.1, 24.8)  0.87 (0.80, 1.32) 14.6 (7.8, 17.8)  0.81 (0.50, 1.36)  1.73 (1.20, 2.47)*  1.42 (0.82, 1.86) 
Miscarriage (n=39)  18.3 (15.2, 27.3)  0.97 (0.81, 1.45)   9.9 (5.4, 19.7)**  0.59 (0.31, 1.18)*  1.85 (0.97, 3.25)*  1.56 (0.78, 2.55)* 
Stillbirth (n=23)  19.0 (15.1, 26.6)  0.93 (0.77, 1.37)  17.2 (10.9, 28.6)  1.04 (0.71, 1.63)  1.10 (0.70, 1.48)  0.84 (0.56, 1.12) 
 
 * P<0.05; **P<0.001 for difference by using Kruskall-Wallis test; SGA: Small for gestational age; SD: Standard deviation; IQR: Interquartile range; MoM: Multiple of the media
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Table 3. Logistic regression results of Ang-2 and the Ang-1/Ang-2 ratio on adverse pregnancy outcomes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Odds ratio using multivariate logistic regression adjusted for maternal age, maternal weight, smoking during pregnancy, previous diagnosed  
hypertension, previous miscarriage, country of birth or socio economic disadvantage; OR: Odds ratio; SGA: Small for gestational age;  
SD: Standard deviation; IQR: Interquartile range; MoM: Multiple of the median; NA: not applicable
     
 
 
Ang-2 (MoM) <10th centile (<0.44) Ang-1 / Ang-2 ratio >90th centile (>1.73) 
Pregnancy outcome 
Affected 
women 
(n) 
Univariate OR 
(95% CI) 
Adjusted OR1       
(95% CI) 
Affected 
women 
(n) 
Univariate OR   
(95% CI) 
Adjusted OR1          
(95% CI) 
SGA<10th centile (n=445) 61 1.40 (1.05, 1.86)  1.41 (1.05, 1.90) 75 1.70 (1.30, 2.23) 1.82 (1.38, 2.39) 
SGA<3rd centile (n=109)                11 0.96 (0.51, 1.80)  0.99 (0.53, 1.88) 19 1.70 (1.03, 2.81) 1.76 (1.05, 2.94) 
Preterm birth <37 weeks (n=311) 43 1.39 (1.00, 1.94) 1.41 (1.00, 1.96) 50 1.60 (1.17, 2.19) 1.63 (1.19, 2.25) 
Preterm birth  <34 weeks (n=85) 11 1.27 (0.67, 2.42) 1.28 (0.68, 2.43) 15 1.76 (1.00, 3.10)  1.77 (1.00, 3.13) 
All preeclampsia (n=163) 20 1.16 (0.72, 1.87) 1.22 (0.75, 1.98) 32 1.99 (1.34, 2.96) 2.09 (1.39, 3.16) 
Early-onset preeclampsia  (n=14) 3 2.27 (0.63, 8.01) 2.18 (0.61, 7.84) 3 2.24 (0.61, 8.14) 2.42 (0.66, 8.87) 
Miscarriage (n=39) 12 3.86 (1.94, 7.70) 3.28 (1.63, 6.60) 17 6.83 (3.53, 13.23)  6.67 (3.44, 12.92) 
Stillbirth (n=23) 1 NA NA 2  0.69 (0.14, 3.32)  0.71 (0.17, 3.02) 
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Table 4: Characteristics of studies assessing Ang-2 during pregnancy      
Reference Country 
Study 
design 
Gestational 
week at 
sampling 
Study outcome n Median Ang-2 (ng/ml) P- value 
 
 
    
Cases Controls  
Wang, 20075 Australia Case-control 10 - 13 SGA & IUGR 
IUGR=13 SGA=8 
Controls=23 
IUGR=14.1            
SGA=29.2  
26.6 
<0.01 
0.53 
Akolekar, 200918 UK Case-control 11 - 13 Preeclampsia 
Preeclampsia=35
Gestational 
hypertension=88 
Controls=214 
Preeclampsia=6.3 
Gestational 
hypertension=6.9 
6.8 NS 
Bolin, 20098 Sweden 
Longitudinal 
cohort 
10 Preeclampsia 
Preeclampsia=19
Controls=43 
13.8 10.2 NS 
Leinonen, 20107 Finland Case-control 12 - 15  
Preeclampsia & 
IUGR 
Preeclampsia=49I
IUGR=16 
Controls=59 
Preeclampsia=38.8 
IUGR=30  
33.2 NS 
Daponte, 20126 Greece Case-control 6 - 8 
Missed abortion 
& ectopic 
pregnancy 
Missed 
abortion=30 
Ectopic 
pregnancy=30 
Missed 
abortion=0.4 
Ectopic 
pregnancy=0.3 
1.4 
<0.001 
<0.001 
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SGA: small for gestational age; IUGR: Intra uterine growth restriction; NS: Not significant
Controls=33 
Schneuer, 2013 Australia Case-cohort 10 - 14 
Various adverse 
pregnancy 
outcomes 
Preeclampsia=163 
SGA=445 
Controls=3444 
Preeclampsia=14.7 
SGA=14.8 
16.6 <0.05 
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                 Figure 1: Scatter plot between Ang-1 and Ang-2 levels.  
 
 
Figure 1: Circles represent each pregnant woman measurement 
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Figure 2: Receiver Operating Characteristic curves comparing first trimester serum Ang-1/Ang-2 
ratio with maternal and clinical risk factors predicting adverse pregnancy outcomes.  
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Figure 2: AUC: Area under the curve. Risk factors are: maternal age, parity, smoking during 
pregnancy, maternal weight, previously diagnosed hypertension, previously diagnosed 
diabetes, country of birth or socio-economic disadvantage 
 
